Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates

分组1 - Niagen Bioscience reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, with an earnings surprise of +100% [1] - The company achieved revenues of $33.84 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 8.81%, compared to $29.13 million in the same quarter last year [2] - Niagen Bioscience has consistently surpassed consensus EPS estimates over the last four quarters [2] 分组2 - The stock has underperformed, losing approximately 23.4% since the beginning of the year, while the S&P 500 has declined by only 0.4% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates at $0.05 for the coming quarter and $0.29 for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Niagen Bioscience belongs, is currently ranked in the bottom 44% of over 250 Zacks industries, indicating potential challenges ahead [8]